These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21149654)

  • 1. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
    Parmar S; Andersson BS; Couriel D; Munsell MF; Fernandez-Vina M; Jones RB; Shpall EJ; Popat U; Anderlini P; Giralt S; Alousi A; Cano P; Bosque D; Hosing C; Silva Lde P; Westmoreland M; Wathen JK; Berry D; Champlin RE; de Lima MJ
    J Clin Oncol; 2011 Jan; 29(3):294-302. PubMed ID: 21149654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
    Poi MJ; Hofmeister CC; Johnston JS; Edwards RB; Jansak BS; Lucas DM; Farag SS; Dalton JT; Devine SM; Grever MR; Phelps MA
    Clin Pharmacokinet; 2013 Aug; 52(8):705-12. PubMed ID: 23588536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
    Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W
    Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.
    Sakai R; Taguri M; Oshima K; Mori T; Ago H; Adachi S; Morita S; Taniguchi S; Fukuda T; Ohashi K; Eto T; Miyamura K; Iwato K; Kobayashi N; Kanamori H; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
    Int J Hematol; 2016 Mar; 103(3):322-33. PubMed ID: 26800676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
    Kharfan-Dabaja MA; Anasetti C; Fernandez HF; Perkins J; Ochoa-Bayona JL; Pidala J; Perez LE; Ayala E; Field T; Alsina M; Nishihori T; Locke F; Pinilla-Ibarz J; Tomblyn M
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1087-93. PubMed ID: 23632090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
    Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
    Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.